News
H.C. Wainwright analyst Matthew Hedberg adjusted the price target on Invivyd Inc. (NASDAQ:IVVD) from $10 to $5, while ...
On Wednesday, H.C. Wainwright analyst Matthew Hedberg adjusted the price target on Invivyd Inc. (NASDAQ:IVVD) from $10 to $5, while maintaining a Buy rating. This revision follows a revenue ...
May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive ...
Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ETCompany ParticipantsKatie Falzone - Senior Vice President, ...
15d
Invivyd Inc (IVVD) reports a 15% reduction in operating expenses and explores new viral targets, while navigating sales transitions and regulatory hurdles.
FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by th ...
INVIVYD ($IVVD) posted quarterly earnings results on Thursday, May 15th. The company reported earnings of -$0.14 per share, missing estimates of -$0.03 by $0.11. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback